EXEL · NASDAQ
Exelixis, Inc.
$64.00 -0.61 (-0.93%)
Company overview
Exelixis, Inc., an oncology-focused biotechnology company, discovers, develops, and commercializes new medicines for the treatment of cancer in the United States. Its products include CABOMETYX tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy, and COMETRIQ capsules for patients with progressive and metastatic medullary thyroid cancer. CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, a MEK inhibitor used in combination regimens to treat advanced melanoma, and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for hypertension treatment in Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $16.1B
- Employees
- 1,147
- Headquarters
- Alameda, CA
- Website
- exelixis.com
- CEO
- Michael Morrissey
- Listed
- April 17, 2000
- P/E
- 20.51
- Dividend yield
- 0.00%
Company financials
- Revenue
- $2.4B
- Gross profit
- $2.3B
- Operating income
- $937M
- EBITDA
- $999M
- Net income
- $833M
- EPS
- $3.12
- Total assets
- $2.6B
- Total debt
- $170M
- Gross margin
- 96.44%
- Net margin
- 35.08%
- Earnings yield
- 4.88%
Showing FY 2025
EXEL
1D
NASDAQ
O65.15H65.20L63.91C64.53-0.78 (-1.19%)Vol2.07M